Top of this page
Skip navigation, go straight to the content
Since 2015, UCB has embarked on a very important change journey:
the Patient Value Strategy
We are now entering its next?phase which we call?
“Accelerate & Expand”?
?
We will accelerate our growth potential by maximizing patients’ access to our key medicines, by further improving our ability to demonstrate differentiation and by accelerating the development timelines through new approaches.
The successful evolution of our late stage pipeline requires additional resources in the short-term therefore we will continue to invest significantly into R&D to deliver breakthrough medicines with sustainable value propositions for patients, healthcare professionals and payers and securing UCB sustainability.
Thanks to its strong financial foundations, UCB will selectively use its financial and strategic flexibility to complement its internal pipeline with external innovative assets, programs or platforms through partnerships, licenses or acquisitions.
?
Continued growth
driven by our key medicines
- Cimzia? growth + expand reach to non-radiographic?axial spondylarthritis?patients in the U.S.
- Vimpat? & Briviact? expand to more and more epilepsy patients
- Keppra? & Neupro?
?
6 potential launches* in the next 5 years
- Romosozumab in post fracture osteoporosis?
- Midazolam nasal spray in acute repetitive epilepsy seizures?
- Bimekizumab in psoriasis, psoriatic arthritis, axial spondyloarthritis ?
- Rozanolixizumab in Immune ThrombocytoPenia, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy?
- Padsevonil in drug-resistant epilepsy ?
- Anti-Tau in progressive supranuclear palsy
?
*?subject to approval
Our key medicines
We bring solutions to people living with neurological or immunological diseases.
In these areas, we have 5 main medicines on the market.
Immunology
Peak sales guidance
?
- Neupro? ~ 2018 level ?
- Vimpat? > € 1.4 billion by 2022 ?
- Cimzia? > € 1.7 billion by 2024 ?
- Briviact? > € 600 million by 2026
Our pipeline
In a challenging environment, our pipeline builds the basis of UCB’s sustainable long term growth.
To create a pipeline that will make a real difference in people’s lives, we have to remain focused on our key assets: our expertise in small and large molecules and our expertise in the fields of neurology and auto-immune diseases.
For a company of our size, we consider it is vital to remain focused.
?
6 potential launches* in the next 5 years
- Romosozumab in post fracture osteoporosis?
- Midazolam nasal spray in acute repetitive epilepsy seizures?
- Bimekizumab in psoriasis, psoriatic arthritis, axial spondyloarthritis ?
- Rozanolixizumab in Immune ThrombocytoPenia, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy?
- Padsevonil in drug-resistant epilepsy ?
- Anti-Tau in progressive supranuclear palsy
?
*?subject to approval
July 2019
CIDP: Chronic Inflammatory Demyelinating Polyneuropathy
?
Changes since February 2019:
- Evenity? (romosozumab) approval in osteoporosis in postmenopausal women at high risk for fracture (U.S. - April 2019) & CHMP negative opinion (June 2019)
- midazolam: approval (U.S. - May 2019)
- bimekizumab: Phase 3 start in psoriatic arthritis (March 2019)
- bimekizumab: Phase 3 start in axial spondyloarthritis (April 2019)
- padsevonil: Phase 3 start in drug resistant epilepsy (March 2019)
- rozanolixizumab: Phase 3 start in?myasthenia gravis?(June 2019)
- rozanolixizumab: Phase 2b start in CIDP (March 2019)
- UCB0159 terminated